Human monoclonal antibodies for prophylaxis and therapy of viral infections

New Concepts of Antiviral Therapy

Volumn , Issue , 2006, Pages 479-505

  Ter Meulen, Jan ^a   Goudsmit, Jaap ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954954815     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-31047-3_18     Document Type: Chapter

References (93)

1. Alfthan K, 1998, Surface plasmon resonance biosensors as a tool in antibody engineering. Biosensors & Bioelectronics 13:653-663.
2. Arakelov S, Gorny MK, Williams C, Riggin CH, Brady F, Collett MS, Zolla-Pazner S, 1993, Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. J. Infect. Dis. 168:580-585.
3. Baker M, 2005, Upping the ante on antibodies. Nat. Biotechnol. 23:1065-1072.
4. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, De Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J, 2005, Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79:9062-9068.
5. Barnard DL, 2004, Inhibitors of measles virus. Antivir. Chem. Chemother. 15:111-119.
6. Bjorling E, Von Garrelts E, Morner A, Ehnlund M, Persson MA, 1999, Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. J. Gen. Virol. 80:1987-1993.
7. Boder ET, Midelfort KS, Wittrup KD, 2000, Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. USA 97:10701-10705.
8. Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA, 2001, Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7:343-51.
9. Bonaros NE, Kocher A, Dunkler D, Grimm M, Zuckermann A, Ankersmit J, Ehrlich M, Wolner E, Laufer G, 2004, Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 77:890-7.
10. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB; AACTG 266 Team, 2004, A phase II, double-masked, randomized, placebocontrolled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 64:103-11.
11. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, Herrero JI, Jardi R, Cruz De Castro E, Garcia-Rey C, 2003, A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J. Hepatol. 38:811-817.
12. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA, 2005, Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. USA 102:13372-13377.
13. Casadevall A, Dadachova E, Pirofski LA, 2004, Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2:695-703.
14. Chou TC, Talalay P, 1984, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
15. Chowdhury PS, Pastan I, 1999, Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17:568-572.
16. Daffis S, Kontermann RE, Korimbocus J, Zeller H, Klenk HD, Ter Meulen J, 2005, Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology 337:262-272.
17. De Carvalho Nicacio C, Lundkvist A, Sjolander KB, Plyusnin A, Salonen EM, Bjorling E, 2000, A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. J. Med. Virol. 60:446-454.
18. De Carvalho Nicacio C, Williamson RA, Parren PW, Lundkvist A, Burton DR, Bjorling E, 2002, Neutralizing human Fab fragments against measles virus recovered by phage display. J. Virol. 76:251-258.
19. De Kruif J, Boel E, Logtenberg T, 1995, Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol Biol. 248:97-105.
20. Dezube BJ, Doweiko JP, Prope JA, Conway B, Hwang L, Terada M, Leece BA, Ohno T, Mastico RA, 2004, Monoclonal antibody hNM01 in HIV-infected patiets: a phase 1 study. J. Clin. Virol. 31 S: S45-S47.
21. Enssle K, Kurrle R, Kohler R, Muller H, Kanzy EJ, Hilfenhaus J, Seiler FR, 1991, A rabiesspecific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10:547-556.
22. Eren R, Ilan E, Nussbaum O, Lubin I, Terkieltaub D, Arazi Y, Ben-Moshe O, Kitchinzky A, Berr S, Gopher J, Zauberman A, Galun E, Shouval D, Daudi N, Eid A, Jurim O, Magnius LO, Hammas B, Reisner Y, Dagan S, 2000, Preclinical evaluation of two human antihepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 32:588-596.
23. Eren R, Lubin I, Terkieltaub D, Ben-Moshe O, Zauberman A, Uhlmann R, Tzahor T, Moss S, Ilan E, Shouval D, Galun E, Daudi N, Marcus H, Reisner Y, Dagan S, 1998, Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system. Immunology 93:154-161.
24. Ferrantelli F, Ruprecht RM (2002). Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol. 14:495-502.
25. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM, 2004, Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189:2167-2173.
26. Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keeffe EB, Matot E, Mizrachi S, Terkieltaub D, Zohar M, Lubin I, Gopher J, Shouval D, Dagan S, 2002, Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology. 35:673-679.
27. Goncalvez AP, Men R, Wernly C, Purcell RH, Lai CJ, 2004, Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J. Virol. 78:12910-12918.
28. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM, 2005, Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191:507-514.
29. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC, Hoogenboom HR, Winter G, 1993, Human anti-self antibodies with high specificity from phage display libraries. EMBO 12:725-734.
30. Griffin D, Levine B, Tyor W, Ubol S, Despres P, 1997, The role of antibody in recovery from alphavirus encephalitis. Immunol. Rev. 159:155-161.
31. Habersetzer F, Fournillier A, Dubuisson J, Rosa D, Abrignani S, Wychowski C, Nakano I, Trepo C, Desgranges C, Inchauspe G, 1998, Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249:32-41.
32. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW, Martin P, 2000, An efficacy and costeffectiveness analysis of combination hepatitis B immuneglobulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 6:741-8.
33. Hanlon CA, De Mattos CA, De Mattos CC, Niezgoda M, Hooper DC, Koprowski H, Notkins A, Rupprecht CE, 2001, Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19:3834-42.
34. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM, 2005, Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2308:1906-1908.
35. He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A, 2002, Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J. Immunol. 169:595-605.
36. Higo-Moriguchi K, Akahori Y, Iba Y, Kurosawa Y, Taniguchi K, 2004, Isolation of human monoclonal antibodies that neutralize human rotavirus. J. Virol. 78:3325-3332.
37. Hollinger P, Hudson PJ, 2005, Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 9:1126-1136.
38. Hong HJ, Ryu CJ, Hur H, Kim S, Oh HK, Oh MS, Park SY, 2004, In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318:134-141.
39. Hoogenboom H, 2005, Selecting and screening recombinant antibody libraries. Nature Biotechnology 23:1105-1116.
40. Hoogenboom HR, De Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC, 1998, Antibody phage display technology and its applications. Immunotechnology 4:1-20.
41. Iacono-Connors LC, Smith JF, Ksiazek TG, Kelley CL, Schmaljohn CS, 1996, Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibody. Virus Res. 43:125-136.
42. Jahrling PB, Peters CJ, Stephen EL, 1984, Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgous monkeys. J. Infect. Dis. 149:420-427.
43. Jakobovits A., 1998, Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci. Adv. Drug. Deliv. Rev. 31:33-42.
44. Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, Prince GA, Koenig S, Young JF, Dillon SB, 1999, A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J. Infect. Dis. 180:35-40.
45. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF, 1997, Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
46. Karasu Z, Ozacar T, Akyildiz M, Demirbas T, Arikan C, Kobat A, Akarca U, Ersoz G, Gunsar F, Batur Y, Kilic M, Tokat Y, 2004, Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther. 9:921-7.
47. Kausmally L, Waalen K, Lobersli I, Hvattum E, Berntsen G, Michaelsen TE, Brekke OH, 2004, Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library. J. Gen. Virol. 85:3493-3500.
48. Keck ZY, Sung VM, Perkins S, Rowe J, Paul S, Liang TJ, Lai MM, Foung SK, 2004, Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78:7257-7263.
49. Kellermann SA, Green LL, 2002, Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 13:593-597.
50. Kim SJ, Jang MH, Stapleton JT, Yoon SO, Kim KS, Jeon ES, Hong HJ, 2004, Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology 318:598-607.
51. Klasse PJ and Sattentau QJ, 2002, Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83:2091-2108.
52. Klonisch T, Panayotou G, Edwards P, Jackson AM, Berger P, Delves PJ, Lund T, Roitt IM, 1996, Enhancement in antigen binding by a combination of synergy and antibody capture. Immunology 89:165-171.
53. Koch J, Liang M, Queitsch I, Kraus AA, Bautz EK, 2003, Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology 308:64-73.
54. Koefoed K, Farnaes L, Wang M, Svejgaard A, Burton DR, Ditzel HJ, 2005, Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs. J. Immunol. Methods. 297:187-201.
55. Kontermann RE, Dübel S (Eds.), 2001, Antibody engineering, Springer, Heidelberg.
56. Kramer RA, Cox F, Van Der Horst M, Van Der Oudenrijn S, Res PC, Bia J, Logtenberg T, De Kruif J, 2003, A novel helper phage that improves phage display selection efficiency by preventing the amplification of phages without recombinant protein. Nucleic Acids Res. 31:e59
57. Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van Der Horst M, Bakker AQ, De Jong M, Jongeneelen M, Thijsse S, Backus HH, Rice AB, Weldon WC, Rupprecht CE, Dietzschold B, Bakker AB, De Kruif J, 2005, The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur. J. Immunol. 35:2131-45.
58. Li A, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, Chou TC, Baba TW, Ruprecht RM, 1998, Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer antihuman immunodeficiency virus type 1 immuoglobulins. J. Virol. 72:3235-3240.
59. Liang M, Mahler M, Koch J, Ji Y, Li D, Schmaljohn C, Bautz EK, 2003, Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J. Med. Virol. 69:99-107.
60. Lipovsek D, Pluckthun A, 2004, In-vitro protein evolution by ribosome display and mRNA display. J. Immunol. Methods 290:51-67.
61. Lonberg N, 2005, Human antibodies from transgenic animals. Nat. Biotechnol. 23:1117-1125.
62. Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van Der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, De Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB, 2005, Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J. Virol. 79:4672-8.
63. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS, 2002, Broadly crossreactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 99:6913-6918.
64. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W, 1997, A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutininspecific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71:4347-4355.
65. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, De Man RA, Bassendine M, O'Grady JG, Portmann BC, Anschuetz G, Barrett CA, Williams R, Atkins M, 2001, Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J. Hepatol. 34:888-894.
66. Nejatollahi F, Hodgetts SJ, Vallely PJ, Burnie JP, 2002, Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol. Med. Microbiol. 34:237-244.
67. Parren PW, Burton DR., 2001, The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77:195-262.
68. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR., 2002, Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76:6408-6412.
69. Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PW, Mosier DE, Burton DR, 1999, Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10:431-438.
70. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, 1994, A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10:1651-1658.
71. Rehermann B, Nascimbeni M, 2005, Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215-229.
72. Reichert JM, Rosenzweig CJ, Faden LB, Dewitz MC, 2005, Monoclonal antibody successes in the clinic. Nat. Biotechnol. 9:1073-1078.
73. Sawyer LA, 2000, Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 47:57-77.
74. Schmaljohn C, Cui Y, Kerby S, Pennock D, Spik K. Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library. Virology 258:189-200.
75. Schofield DJ, Glamann J, Emerson SU, Purcell RH, 2000, Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J. Virol. 74:5548-5555.
76. Seiler P, Senn BM, Klenermann P, Kalinke U, Hengartner H, Zinkernagel RM, 2000, Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persisence. J. Virol. 74:5896-5901.
77. Steinitz M, Klein G, Koskimies S, Makel O., 1977, EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269:420-2.
78. Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, Jagodzinski LL, Ammann C, Jager W, Jacobson J, Vetter N, Katinger H, 2002, Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 16:2019-2025.
79. Stogner SW, King JW, Black-Payne C, Bocchini J., 1993, Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South. Med. J. 86:1415-8.
80. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA, 2004, Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 101:2536-2541.
81. Ter Meulen J, Bakker AB, Van Den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, De Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD, 2004, Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363:2139-41.
82. Thompson J, Pope T, Tung JS, Chan C, Hollis G, Mark G, Johnson KS, 1996, Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J. Mol. Biol. 256:77-88.
83. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A., 2004, An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-5.
84. Van Den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, De Kruif J, Goudsmit J, 2005, Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 79:1635-44.
85. Wang CY, Sawyer LS, Murthy KK, Fang X, Walfield AM, Ye J, Wang JJ, Chen PD, Li ML, Salas MT, Shen M, Gauduin MC, Boyle RW, Koup RA, Montefiori DC, Mascola JR, Koff WC, Hanson CV, 1999, Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc. Natl. Acad. Sci. USA. 96:10367-10372.
86. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar, MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM, 2003, Antibody neutralization and escape by HIV-1. Nature 422:307-312.
87. Wolbank S, Kunert R, Stiegler G, Katinger H, 2003, Characterization of human classswitched polymeric (Immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 77:4095-4103.
88. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350:126-144.
89. Xu W, Smith-Franklin BA, Li PL, Wood C, He J, Du Q, Bhat GJ, Kankasa C, Katinger H, Cavacini LA, Posner MR, Burton DR, Chou TC, Ruprecht RM, 2001, Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J. Hum. Virol. 4:55-61.
90. Yang W-P, Green K, Pinz-Sweeny S, Briones AT, Buron DR, Barbas CF, 1995, CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV antibody into the picomolar range. J. Mol. Biol. 254:392-403.
91. Zwick MB, Parren PW, Saphire EO, Church S, Wang M, Scott JK, Dawson PE, Wilson IA, Burton DR, 2003, Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77:5863-5876.
92. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, Burton DR, Parren W, 2001, Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75:12198-12208.
93. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR, 2005, Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol. 79:1252-1261.